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(NOA). The recent discovery of NOA in 
Southern Nevada has raised our interest 
in the surveillance of mesothelioma in 
the region.” So it appears we all agree 
that our findings identifying environ-
mental exposure to asbestos in Southern 
Nevada are important and require fol-
low-up because asbestos causes meso-
thelioma. Therefore, we are puzzled by 
the title of their letter, a title that can-
not be supported by data, and that in 
fact contradicts published evidence that 
exposure to asbestos increases the risk 
of mesothelioma and that such expo-
sure is occurring in Southern Nevada.8–10 
Risk is defined as the product of haz-
ard and vulnerability (or exposure).11 
Southern Nevadans are indeed being 
exposed to the hazard of asbestos fibers 
and therefore are at increased risk for 
mesothelioma and other asbestos-related 
diseases.1,12 For example, ambient air 
measured for phase I of the Boulder city 
bypass showed the presence of airborne 
asbestos fibers.10 Moreover, some indi-
viduals may be exposed to significantly 
higher concentrations through recre-
ational activities, such as off-road vehicle 
recreation, horseback riding, mountain 
bicycle riding, hiking, and other activi-
ties that are popular in the desert areas 
where asbestos fibers occur.1,8–10,13
Environmental epidemiology is 
about identifying areas in which envi-
ronmental risk exists and work with 
local experts and authorities to elimi-
nate or at least mitigate the risk. We 
hope that we will be allowed to further 
investigate the areas in Southern Nevada 
where exposure occurs and where there 
is an apparent increase of mesothelioma 
among young adults. We would welcome 
the opportunity to work together with 
Nevada epidemiologists and the Nevada 
health authorities to help identify mea-
sures to reduce environmental exposure 
to asbestos and to other carcinogenic 
fibers and the consequent risk of meso-
thelioma, as we have done in other parts 
of the US and of the world.6,13,14
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To the Editor:
We read with great interest the 
recent article by Hoffknecht et al.1 
on the efficacy of afatinib for central 
nervous system (CNS) metastases in 
patients who had undergone first-gen-
eration epidermal growth factor recep-
tor (EGFR)-tyrosine kinase inhibitors 
(TKIs). We also present a case with 
EGFR-mutant non–small-cell lung 
cancer whose erlotinib refractory brain 
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“pharmacokinetic failure.” To over-
come this CNS-specific resistant 
mechanism, high-dose EGFR-TKIs 
have been administered.3,4 However, 
the efficacy of this strategy may be 
only moderate.5 Their study and our 
case have demonstrated the high 
potency of “high affinity” second-
generation irreversible EGFR-TKIs, 
such as afatinib, against refractory 
CNS metastases, instead of “high-
dose” first-generation reversible 
EGFR-TKIs, such as gefitinib and 
erlotinib. Further studies are needed 
to confirm the efficacy of afatinib for 
first-generation TKI refractory CNS 
metastases.
Akito Hata, MD
Nobuyuki Katakami, MD, PhD
Division of Integrated Oncology
Institute of Biomedical 
Research and Innovation
Kobe, Japan 
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metastases (BM) markedly responded 
to afatinib despite a nonresponse in 
extra-CNS lesions.
A 70-year-old woman was 
diagnosed with non–small-cell lung 
cancer harboring EGFR mutation in 
exon 21 (L858R). Cervical lymph 
node metastases were confirmed, rep-
resenting a metastatic disease. She 
received cisplatin plus docetaxel as 
first-line chemotherapy. After pro-
gressive disease, erlotinib was admin-
istered as second-line therapy. Partial 
response was achieved, but new 
BM were detected 1 year after erlo-
tinib administration (Fig. 1A and B). 
Afatinib (50 mg/day) was then initi-
ated as third-line therapy. Despite 
stable disease on extra-CNS lesions, 
BM responded well to afatinib (Fig. 
1C and D). Dose reduction to 40 mg/
day was performed because of grade 
3 diarrhea. Clinical benefit contin-
ued for 4 months, but cervical lymph 
node metastases progressed, whereas 
BM response remained. Rebiopsy was 
performed on the cervical lymph node 
metastases, and T790M was negative.
Study of Hoffknecht et al. has a 
limitation. They did not a consider TKI-
free interval between the prior first-gen-
eration TKI and afatinib, which could 
restore TKI sensitivity. Even though it 
was not afatinib, first-generation TKI 
rechallenge could respond after TKI-
free interval.2 However, in our present 
case, afatinib was directly switched 
from erlotinib without TKI-free inter-
val. This suggested a pure potent effi-
cacy of afatinib for refractory CNS 
metastases over standard dose erlotinib.
In our case, erlotinib refrac-
tory BM markedly responded to 
afatinib despite a nonresponse in 
extra-CNS lesions. This paradoxical 
response implicates differential resis-
tant mechanisms between CNS and 
extra-CNS lesions. Rebiopsy result 
in cervical lymph node revealed 
T790M-negative, suggesting EGFR 
signal nondependant resistant mecha-
nisms in extra-CNS lesions. On the 
other hand, CNS-resistant mecha-
nism appears to cause a poor TKI 
penetration into CNS, which is called 
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FIGURE 1.  Two brain metastases (arrow and arrowhead) in brain magnetic reso-
nance imagings before afatinib initiation (A and B), and after 2 months (C and D).
